For the FLT3-ITDhigh/NPM1mut (n = 13), FLT3-ITDlow/NPM1wt (n = 9), and FLT3-ITDhigh/NPM1wt AML (n = 8) groups, the OS and RFS at 2 years after HSCT did not significantly differ (46.2%, 44.4%, and 50% for OS (p = 0.795, Figure 4A) and 30.0%, 33.3%, and 36.4% for RFS (p = 0.9, Figure 4B), respectively). The gene discussed is FLT3; the disease is acute myeloid leukemia.